The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

Sarepta will sell back $50 million worth of shares to cover part of a $100 million milestone payment and its remaining shares worth $174 million.

The firm now expects its cash runway to extend to 2028, bolstered by having recently raised $244 million via a private placement and an at-the-market issuance.

Researchers at three Boston institutions are advancing a ctDNA assay with the goal of getting more children with solid tumors into biomarker-directed therapies and trials.

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.

The firm is touting its AI-driven foundation model's ability to predict how any patient will respond to any drug, allowing sponsors to fine-tune their trials.

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

BUFFALO, NY – Five major research centers in New York have banded together to share resources and a manufacturing facility in ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.